Alessandra Iurlo

Ontology type: schema:Person     

Person Info





Publications in SciGraph latest 50 shown

  • 2021-11-26 Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience in BLOOD CANCER JOURNAL
  • 2021-06-16 Long-term follow-up of recovered MPN patients with COVID-19 in BLOOD CANCER JOURNAL
  • 2021-05-19 Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients in LEUKEMIA
  • 2021-03-06 Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program in BLOOD CANCER JOURNAL
  • 2021-02-04 Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 in BLOOD CANCER JOURNAL
  • 2021-01-07 High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib in LEUKEMIA
  • 2021-01-07 Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) in ANNALS OF HEMATOLOGY
  • 2021-01-07 Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis in BLOOD CANCER JOURNAL
  • 2021-01-03 Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib in ANNALS OF HEMATOLOGY
  • 2020-12-01 BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS in LEUKEMIA
  • 2020-08-25 COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey in LEUKEMIA
  • 2020-07-03 How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey in LEUKEMIA
  • 2020-06-18 Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey in LEUKEMIA
  • 2020-06-08 Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study in BLOOD CANCER JOURNAL
  • 2020-05-30 Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors in ANNALS OF HEMATOLOGY
  • 2020-05-26 Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality in LEUKEMIA
  • 2020-04-30 Management of Myelofibrosis: from Diagnosis to New Target Therapies in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2020-02-11 Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study in LEUKEMIA
  • 2019-12-05 Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2019-09-16 Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy in ANNALS OF HEMATOLOGY
  • 2019-09-02 Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy in LEUKEMIA
  • 2019-08-07 Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline in ANNALS OF HEMATOLOGY
  • 2019-05-29 Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study in LEUKEMIA
  • 2019-05-01 Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice in ANNALS OF HEMATOLOGY
  • 2018-12-04 Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib in ANNALS OF HEMATOLOGY
  • 2018-06-01 The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting in BLOOD CANCER JOURNAL
  • 2018-04-19 Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice in ANNALS OF HEMATOLOGY
  • 2018-02-28 Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms in BLOOD CANCER JOURNAL
  • 2018-02-22 Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment in ANNALS OF HEMATOLOGY
  • 2018-01-23 Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option in CLINICAL DRUG INVESTIGATION
  • 2017-10-02 Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series in ANNALS OF HEMATOLOGY
  • 2017-08-19 Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2017-06-30 Erratum: The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations in MODERN PATHOLOGY
  • 2017-06-12 Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine in QUALITY OF LIFE RESEARCH
  • 2016-11-04 Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients in BLOOD CANCER JOURNAL
  • 2016-10-14 The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations in MODERN PATHOLOGY
  • 2016-09-05 CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis in ANNALS OF HEMATOLOGY
  • 2016-08-02 In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants in BMC CANCER
  • 2016-08-01 Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature in PATHOLOGY & ONCOLOGY RESEARCH
  • 2016-06-03 Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis in SUPPORTIVE CARE IN CANCER
  • 2016-04-26 High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists in LEUKEMIA
  • 2016-04-04 Anagrelide and Mutational Status in Essential Thrombocythemia in BIODRUGS
  • 2016-02-12 Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients in LEUKEMIA
  • 2015-11-07 The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2015-09-04 Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications in MODERN PATHOLOGY
  • 2015-06-19 Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib in LEUKEMIA
  • 2015-06-18 Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib in ANNALS OF HEMATOLOGY
  • 2014-11-08 Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis in ANNALS OF HEMATOLOGY
  • 2013-11-08 Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms in MODERN PATHOLOGY
  • 2013-06-21 Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage in MODERN PATHOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

        "@context": "", 
        "affiliation": [
            "affiliation": {
              "id": "", 
              "type": "Organization"
            "isCurrent": true, 
            "type": "OrganizationRole"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
            "id": "", 
            "type": "Organization"
        "familyName": "Iurlo", 
        "givenName": "Alessandra", 
        "id": "sg:person.0707634643.36", 
        "identifier": [
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0002-4401-0812"
        "sameAs": [
        "sdDataset": "persons", 
        "sdDatePublished": "2022-01-01T19:57", 
        "sdLicense": "", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/person/person_817.jsonl", 
        "type": "Person"

    Download the RDF metadata as:  json-ld nt turtle xml License info


    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' ''

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' ''

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' ''

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' ''


    This table displays all metadata directly associated to this object as RDF triples.

    31 TRIPLES      11 PREDICATES      18 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.0707634643.36 schema:affiliation N36714455485e4507afc5081da606ccb6
    2 grid-institutes:grid.18887.3e
    3 grid-institutes:grid.257413.6
    4 grid-institutes:grid.413179.9
    5 grid-institutes:grid.4708.b
    6 grid-institutes:grid.7605.4
    7 schema:familyName Iurlo
    8 schema:givenName Alessandra
    9 schema:identifier N0d4429d6ff2c4530b74f5176ccfcc859
    10 schema:sameAs
    12 schema:sdDatePublished 2022-01-01T19:57
    13 schema:sdLicense
    14 schema:sdPublisher N795e142de8824201ba68c69e3c3277a1
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset persons
    17 rdf:type schema:Person
    18 N0d4429d6ff2c4530b74f5176ccfcc859 schema:name orcid_id
    19 schema:value 0000-0002-4401-0812
    20 rdf:type schema:PropertyValue
    21 N36714455485e4507afc5081da606ccb6 schema:affiliation grid-institutes:grid.414818.0
    22 sgo:isCurrent true
    23 rdf:type schema:OrganizationRole
    24 N795e142de8824201ba68c69e3c3277a1 schema:name Springer Nature - SN SciGraph project
    25 rdf:type schema:Organization
    26 grid-institutes:grid.18887.3e schema:Organization
    27 grid-institutes:grid.257413.6 schema:Organization
    28 grid-institutes:grid.413179.9 schema:Organization
    29 grid-institutes:grid.414818.0 schema:Organization
    30 grid-institutes:grid.4708.b schema:Organization
    31 grid-institutes:grid.7605.4 schema:Organization

    Preview window. Press ESC to close (or click here)